证券代码：688261 证券简称：东微半导 公告编号：2025-026 苏州东微半导体股份有限公司 第二届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 苏州东微半导体股份有限公司（以下简称"公司"）第二届董事会第十二次 会议于 2025 年 7 月 15 日在公司会议室以现场结合通讯的方式召开。本次会议通 知已于 2025 年 7 月 10 日以邮件方式送达公司全体董事。本次会议由董事长龚轶 先生主持。会议应出席董事 8 人，实际出席董事 8 人。 本次会议的召集、召开符合有关法律、法规及规章制度和《苏州东微半导体 股份有限公司章程》（以下简称《公司章程》）的有关规定。出席会议的全体董事 对议案进行了认真审议和表决，形成以下决议： 二、董事会会议审议情况 （一）审议通过《关于取消监事会、调整董事会人数、修订<公司章程>并办 理工商变更登记的议案》 董事会认为：根据《公司法》《上市公司章程指引（2025 年修订）》等有 关法律法规的规定，结合公司实际情况，取消监事会、调整 ...

Group 1 - The A-share semiconductor sector showed strong performance during trading, with significant gains in various stocks [1] - Hongwei Technology surged over 16%, while Cambricon, Xiangjie Technology, and Dongwei Semiconductor all increased by over 7% [1] - Other companies such as Chipone Technology and Chipsea Technology also saw gains exceeding 4% [1]

Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]

Core Viewpoint - The MOSFET industry in China is experiencing significant growth driven by the demand from sectors such as consumer electronics, communication, industrial control, and automotive electronics, with a projected market size of 42.944 billion yuan in 2024, reflecting a year-on-year growth of 7.67% [1][11]. Industry Overview - MOSFET (Metal-Oxide-Semiconductor Field-Effect Transistor) is a semiconductor device that controls current using electric fields, consisting of a metal gate, an insulating oxide layer, and a semiconductor substrate [2]. - The industry has evolved through four main stages, from initial development before 2010 to the current phase of domestic substitution, where local manufacturers are increasingly producing high-end products [4][5]. Industry Development History - The industry has transitioned from a pioneering phase before 2010 to a period of local alliances from 2011 to 2013, followed by structural reforms from 2014 to 2016, and now to a phase of domestic substitution since 2017 [4][5]. Industry Supply Chain - The upstream of the MOSFET industry includes raw materials and production equipment, while the midstream focuses on manufacturing, and the downstream applications span automotive electronics, consumer electronics, industrial control, and communication devices [7]. Market Size - The demand for MOSFETs is rising due to the proliferation of 5G technology, the boom in the electric vehicle market, and increasing industrial automation [11]. - The performance of silicon-based MOSFETs is improving, and third-generation semiconductor devices like SiC MOSFETs are being commercialized, enhancing charging efficiency and range for electric vehicles [11]. Key Companies' Performance - The competitive landscape of the MOSFET industry is characterized by dominance from overseas giants like Infineon and ON Semiconductor, while domestic firms such as Huazhu Microelectronics, Silan Microelectronics, and New Clean Energy are emerging as leaders [13]. - Huazhu Microelectronics reported a revenue of 2.355 billion yuan in Q1 2025, a year-on-year increase of 11.29%, with a net profit of 83 million yuan, up 150.68% [14]. - Silan Microelectronics achieved a revenue of 11.221 billion yuan in 2024, reflecting a growth of 20.14%, with R&D investment reaching 1.084 billion yuan, up 22.93% [16]. Industry Development Trends - The market size of the MOSFET industry is expected to continue expanding, particularly in the electric vehicle sector, where demand for high-performance MOSFETs is increasing [18]. - Technological innovation is accelerating, with third-generation semiconductor materials like SiC and GaN gaining traction, promising higher efficiency and performance [19][20]. - The trend of domestic substitution is strengthening, with local companies improving their competitiveness and reducing reliance on foreign products, while also integrating the supply chain [21].

证券代码：688261 证券简称：东微半导 公告编号：2025-024 苏州东微半导体股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/18 | 2025/6/19 | 2025/6/19 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经苏州东微半导体股份有限公司（以下简称"公司"）2025 年 5 月 20 日的2024年年度股东会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户除外）。 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.03955元（含税） 相关日期 ...

中国国际金融股份有限公司 关于苏州东微半导体股份有限公司 差异化权益分派特殊除权除息事项的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为苏州 东微半导体股份有限公司（以下简称"东微半导"或"公司"）首次公开发行股票并 在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所科创板股票上市规则》等相关法律法规和规范性文件的要求，对东微半导 差异化权益分派特殊除权除息的事项进行了核查，具体核查情况如下： 一、本次差异化权益分派的原因 公司分别于 2023 年 9 月 19 日、2023 年 10 月 9 日召开了第一届董事会第十 九次会议、2023 年第二次临时股东大会，审议通过了《关于以集中竞价交易方 式回购公司股份方案的议案》，同意公司以首次公开发行人民币普通股取得的部 分超募资金通过上海证券交易所交易系统以集中竞价交易方式回购公司股票。本 次回购的资金总额不低于人民币2,500万元（含）且不超过人民币5,000万元（含）， 回购价格不超过人民币 140 元/股（含），回购的股份将在未来适宜时机全部用 于股权激励及/或员工持股计划。回购期限为自公司股东大会审 ...

Core Viewpoint - Dongwei Semiconductor (688261), known as the "first stock of charging pile chips," has seen its stock price plummet nearly 80% from a peak of 179.27 yuan to 38.63 yuan due to the downturn in the power semiconductor industry and increased competition [1] Company Performance - Dongwei Semiconductor was established in 2008 and operates as a fabless manufacturer of power semiconductors, with products widely used in various sectors including 5G base stations, data centers, and electric vehicle charging [1] - The company experienced significant growth from 2020 to 2022, with 2022 revenues reaching 1.116 billion yuan and net profits of 284 million yuan, marking year-on-year increases of 42.72% and 93.57%, respectively [4] - However, in 2023, the company reported a revenue decline of 12.86% to 973 million yuan, with net profit dropping over 50% to 140 million yuan [7][8] Competitive Landscape - Dongwei Semiconductor's gross margin has significantly decreased from 33.96% in 2022 to 22.73% in 2023 and further to 14.29% in 2024, indicating a loss of competitive edge compared to peers [8][9] - The company's inventory turnover efficiency has worsened, with inventory turnover days increasing from 56.31 days in 2021 to 146.74 days in 2024, leading to substantial asset impairment losses [11] New Business Development - Despite ongoing R&D investments and attempts to diversify product offerings, new business lines such as Super Silicon MOSFET and SiC devices have contributed minimally to overall revenue, maintaining a combined share of only about 4% from 2021 to 2024 [13][14] - The SiC market is expected to grow significantly, but Dongwei Semiconductor faces challenges due to its lack of technological advantages and the competitive landscape dominated by established players [17][19]

Investment Rating - The report maintains an investment rating of "Outperform" for the biopharmaceutical sector [7]. Core Insights - The PD-(L)1 monoclonal antibody market is vast, with multiple companies developing PD-1 class upgrade products, including PD-1/VEGF bispecific antibodies and PD-1/IL-2 bispecific antibodies. The IBI363 from Innovent Biologics is expected to be the next significant PD-1 upgrade product following the PD-1/VEGF bispecific antibody [2][21]. - IBI363 has shown excellent data in the treatment of wild-type NSCLC and colorectal cancer, indicating its potential to expand into first-line treatment markets based on its performance in the IO resistant market [2][22]. - The competitive landscape for PD-1/IL-2 bispecific antibodies is favorable for IBI363, as it is the only PD-1/IL-2α bispecific antibody currently in Phase II clinical trials, while most competitors are in earlier stages [3][25]. Summary by Sections Weekly New Drug Market Review - From June 2 to June 6, 2025, the top five companies in the new drug sector by stock performance were Junsheng Tai Pharmaceutical-B (24.29%), Zai Lab (23.28%), Innovent Biologics (18.08%), Maiwei Biopharma (17.72%), and Shenzhou Cell (17.24%). The bottom five were Deqi Pharmaceutical-B (-12.68%), JACOB-B (-11.90%), Heptares Therapeutics-B (-10.86%), CanSino Biologics-B (-10.75%), and WuXi AppTec-B (-8.54%) [1][17]. Weekly New Drug Industry Analysis - The report highlights the potential of IBI363 as a next-generation PD-1 upgrade product, with promising data presented at ASCO 2025. The drug is expected to target multiple tumor types and expand into first-line treatment markets [2][21]. Weekly New Drug Approval & Acceptance Status - This week, 20 new drug or new indication applications were approved in China, including drugs from Zai Lab and Shenzhen Xinlitai. Additionally, 11 new drug applications were accepted, including those from MSD and Eli Lilly [4][28]. Weekly New Drug Clinical Application Approval & Acceptance Status - There were 21 new drug clinical application approvals and 43 new drug clinical applications accepted in the domestic market this week [5].

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The stroke treatment market in China is projected to exceed 100 billion yuan, with QHRD106 from Qianhong Pharmaceutical expected to become a major product with potential sales of 4-5 billion yuan [1][19]. - The A-share pharmaceutical index has shown a year-to-date increase of 6.6%, outperforming the CSI 300 index by 9.0% [4][9]. - The report highlights the importance of secondary prevention in acute ischemic stroke (AIS) treatment, emphasizing the need for effective therapies [18][19]. Summary by Sections Industry Trends - The A-share pharmaceutical index has increased by 2.6% this week, with significant gains in various sub-sectors, including chemical drugs (+4.4%) and raw materials (+3.2%) [4][9]. - The H-share biotechnology index has shown a year-to-date increase of 41.4%, outperforming the Hang Seng Technology Index [4][9]. Market Potential - The number of stroke patients in China is approximately 13 million, with an annual increase of about 4.5%-4.8%, indicating a growing market for stroke medications [19][27]. - The report estimates that the sales peak for QHRD106 could reach 4-5 billion yuan by 2027, positioning it as a potential blockbuster drug [1][19]. R&D Progress and Company Dynamics - QHRD106 is currently in clinical phase II, with data expected to be released in the second half of 2025, potentially outperforming existing similar drugs [1][19]. - The report lists several companies to watch, including Qianhong Pharmaceutical, Hengrui Medicine, and BeiGene, focusing on growth potential in the innovative drug sector [10][11]. Investment Strategy - Recommended sub-sector rankings for investment are: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [10]. - Specific stock selection strategies include focusing on growth in innovative drugs and identifying undervalued stocks in traditional Chinese medicine [10].

中国国际金融股份有限公司 关于苏州东微半导体股份有限公司 核心技术人员离职的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为苏州 东微半导体股份有限公司（以下简称"东微半导"或"公司"）首次公开发行股票并 在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所科创板股票上市规则》等相关法律法规和规范性文件的要求，对东微半导 核心技术人员离职的事项进行了核查，具体核查情况如下： 一、核心技术人员离职的具体情况 公司董事会近日收到公司核心技术人员刘磊先生的辞职申请。刘磊先生因个 人职业发展原因，向公司申请辞去核心技术人员职务，辞职后将不再担任公司任 何职务。 （一）刘磊先生的具体情况 刘磊先生在职期间作为核心技术人员参与公司研发工作，目前已完成工作交 接，其离职不会对公司的技术研发、产品创新、核心竞争力与持续经营能力产生 1 不利影响。 刘磊先生在职期间参与研究并申请的专利等知识产权均为职务成果，截至本 核查意见出具之日，该等职务成果所形成的所有权均属于公司，不涉及权利纠纷 或潜在纠纷，其离职不会影响公司专利等知识产权的完整性。 （三）保密及竞业限制情况 根据公 ...